Research - By Zack Fink and guest contributor Dan Marks Bluebird bio (BLUE) will release data from the first Sickle Cell Disease patient treated with its LentiGlobin gene therapy … Continue Reading
Read nowRecap - In biotech investing, rarely do five trading sessions go by without some explosive volatility. This week, it was Merck’s (MRK) acquistion of Cubist Pharmaceuticals (CBST) for $9 billion, and bluebird … Continue Reading
Read nowResearch - Bluebird Bio (BLUE) surprised everyone on Monday evening, exceeding expectations for early data from the LentiGlobin drug candidate.
Read nowRecap - The American Society of Hematology’s annual meeting begins this weekend in San Francisco. It’s a big event for the oncology research community, particularly those studying blood cancers, … Continue Reading
Read nowRecap - As expected, Trillium Therapeutics (SCTPF)(TR.TO) announced this week an upcoming reverse-split, NASDAQ uplisting, and reiterated the timeline for bringing its SIRPaFc antibody-like fusion proteins into the clinic … Continue Reading
Read nowResearch - Last week, preliminary data for bluebird bio (BLUE)’s Lentiglobin were released as part of the abstract dump for ASH in December (we wrote at length about this, here). Bluebird … Continue Reading
Read nowResearch - The American Society of Hematology’s annual meeting (56th!) begins on December 6, but abstracts from the conference will be released this morning. This, and the … Continue Reading
Read now
